Connect with us

Trends

Epigenetics market to reach USD 6.33B by 2031

The epigenetics market is projected to reach $6.33 billion by 2031 at a CAGR of 15.7% from 2024 to 2031.

Epigenetics is a phenotypic alteration without permanent genotypic change using several methods, including DNA methylation, histone modification, RNA modification, etc. These modifications play a crucial role in diagnosing and prognosis diseases and disorders. Epigenetics finds its major application in oncology due to the global cancer burden and the growing adoption of precision cancer therapies.

The growth of the epigenetics market is driven by the rising incidence of chronic diseases due to the rising aging population, the increasing prevalence of cancer, rising pharmaceutical R&D expenditures, the increasing focus on epigenetics in drug discovery & development, and the declining costs of genome sequencing. However, the lack of skilled professionals restrains the growth of this market.

The growing applications of epigenetics in non-oncology diseases and government initiatives supporting large-scale genomic sequencing projects are expected to generate growth opportunities for the stakeholders in this market. However, standardization concerns associated with epigenetics procedures and the limited applications of epigenetics in toxicology are major challenges to market growth.

Epigenetics enables pharmaceutical & biotechnology companies to identify and validate disease interactions and mechanisms that can be used in developing new diagnostic tests and therapies. Epigenetic markers are measurable indicators of a biological state or process that can be used to diagnose, monitor, or predict the progression of a disease and identify changes in gene expression, genetic variations, or epigenetic modifications associated with a particular disease or condition.

Biotechnology companies utilize epigenetic methods to identify factors influencing cell or gene interactions, reduce the time required to understand factors causing diseases, and enable early diagnosis and treatment.

The report also includes an extensive assessment of the key strategic developments of leading industry participants over the past three to four years (2021–2024). In the last couple of years, the Epigenetics Market has witnessed several strategic developments.

Among the offerings covered in this report, the epigenetics market is segmented into kits & reagents, software, and services. In 2024, the kits & reagents segment is expected to account for the largest share of around 70% of the epigenetics market. Moreover, the segment is also expected to record the highest CAGR during the forecast period. Kits & reagents are used to study epigenetics through chromatin analysis, histone analysis, DNA methylation, and sequencing, among other methods. Kits are ready-to-use assays that include components such as primers, controls, columns, buffers, beads, inhibitors, and antibodies, depending on the method used for analysis. Reagents are sold separately and can be used in different concentrations depending on the requirements of the procedure/analysis. The recurrent use of kits and reagents and the growing cancer prevalence are the major factors attributed to the segment’s fast growth.

Among the methods covered in this report, the global epigenetics market is segmented into DNA methylation, histone modification, RNA modification, polymerase chain reaction (PCR), chromatin analysis, sonication, and other methods. In 2024, the DNA methylation segment is expected to account for the largest share of the epigenetics market. DNA methylation is an epigenetic mechanism that involves transferring a methyl group onto the C5 position of cytosine to form 5-methylcytosine. This process regulates gene expression by promoting or inhibiting the binding of transcription factors to DNA. The increasing prevalence of cancer, technological advancements in PCR and sequencing, and the high focus on reducing costs associated with lengthy research and product approval processes support the segment’s large share.

Among the applications covered in this report, the global epigenetics market is segmented into oncology and non-oncology. In 2024, the oncology segment is expected to account for the largest share of around 78% of the market. Epigenetics helps differentiate the nuclear organization, DNA methylation, and histone modification patterns between cancer and normal cells. Several changes in cancer cells, such as lower histone post-translational modifications (methylation or acetylation), are associated with poor outcomes in prostate, lung, and kidney cancers. In contrast, higher levels of a specific histone modification (H3K9ac) are associated with lower survival in lung cancer. Also, a reduction in miR-101 expression has been observed in many cancer types, which leads to increased expression of an enzyme responsible for histone methylation. Such methylation induction in tumor suppressor genes can increase the risk of cancer development. Thus, epigenetic analyses help in the study, early diagnosis, and treatment of cancer, leading to a large market share of the segment.

Among the end users covered in this report, the global epigenetics market is segmented into pharmaceutical and biotechnology companies, academic & research institutes, and hospitals & diagnostic laboratories. The pharmaceutical and biotechnology companies’ segment is expected to record the highest CAGR during the forecast period. The rapid growth of this segment is attributed to increasing R&D investments by pharmaceutical & biotechnology companies, the growing prevalence of chronic diseases, and a growing emphasis on personalized medicine.

The utilization of epigenetic analysis is growing in precision medicine. Advancements in epigenetic analysis are changing the way cancer is diagnosed and treated by doctors. New targeted cancer treatments that use genomic data to provide patient-specific treatments are known as precision oncology. This rapidly developing field has already become a part of mainstream clinical practices. It involves the molecular profiling of cancer cells to identify targetable alterations, also known as biomarkers. Quick and reliable sequencing of multiple genes at once is possible with epigenetic analysis. Epigenetic analysis has helped develop precision medicine, which involves tailoring treatments based on disease-causing molecular/epigenetic changes in a person’s body.

Geographically, in 2024, North America is expected to account for the largest share of around 50% of the epigenetics market. North America’s large market share is primarily attributed to the strong focus of local companies on product launches and enhancements, the presence of key players, the established healthcare system, the growing number of chronic diseases, and the rising geriatric population. Meticulous Research®

Copyright © 2024 Medical Buyer

error: Content is protected !!